Skip to main content
Premium Trial:

Request an Annual Quote

Norwegian DNA Analysis Company iSentio Raises $1.5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Norwegian DNA analysis company iSentio today announced it has raised $1.5 million to grow its sales and marketing efforts and accelerate development of new application areas for its RipSeq software.

The funding was led by existing and new investors, including Norwegian seed capital fund, Sarsia Seed, a new investor.

In a statement, the company said that it has had a successful market introduction of its web-based sequence RipSeq software for identifying multiple bacteria after direct sequencing of clinical patient samples. The software is used in hospitals in both Europe and the US.

The new funding was to done to capitalize on the momentum from the launch and will allow the company to expand its presence and address new markets, iSentio CEO Bjarte Karlsen said in a statement.

iSentio also named a new board chairperson, Siri Fürst, who has held various managerial positions at Hafslund, Hafslund Nycomed, and Nycomed Pharma. She was also CEO of DiaGenic.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.